Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$593 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.1
Industry P/E
28.01
EV/EBITDA
-3.5
Div. Yield
0 %
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
49,715,600
CFO
$-339.49 Mln
EBITDA
$-402.86 Mln
Net Profit
$-341.35 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kalvista Pharmaceuticals Inc (KALV)
| 38.1 | 2.0 | -1.6 | -0.3 | 4.1 | -1.9 | -19.5 |
|
BSE Sensex*
| 5.6 | 1.1 | 5.9 | 6.8 | 16.1 | 18.8 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Kalvista Pharmaceuticals Inc (KALV)
| -30.6 | 81.2 | -48.9 | -30.3 | 6.6 | -9.8 | 101.8 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kalvista Pharmaceuticals Inc (KALV)
|
11.7 | 593.1 | 1.2 | -175.9 | -14,601.7 | -110.6 | -- | 4.1 |
| 720.8 | 90,159.5 | 359,051.0 | 3,295.0 | 0.9 | -162.9 | 28.1 | 5.0 | |
| 1.1 | 7.3 | 0.0 | 20.3 | -- | 43.4 | 0.8 | 0.2 | |
| 84.7 | 4,123.2 | 1,137.8 | 214.6 | 29.2 | 12.3 | 19.4 | 2.2 | |
| 2.9 | 4.9 | 14.3 | -3.5 | -21.4 | -65.5 | -- | 1.1 |
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small... molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. Address: 55 Cambridge Parkway, Cambridge, MA, United States, 02142 Read more
CEO & Director
Mr. Benjamin L. Palleiko
CEO & Director
Mr. Benjamin L. Palleiko
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Kalvista Pharmaceuticals Inc (KALV) stood at $ 302 Mln as on 31-Jan-25
The share price of Kalvista Pharmaceuticals Inc (KALV) is $11.70 (NASDAQ) as of 24-Jun-2025 16:02 EDT. Kalvista Pharmaceuticals Inc (KALV) has given a return of 4.14% in the last 3 years.
Kalvista Pharmaceuticals Inc (KALV) has a market capitalisation of $ 593 Mln as on 24-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Kalvista Pharmaceuticals Inc (KALV) is 4.09 times as on 24-Jun-2025, a 13% discount to its peers’ median range of 4.72 times.
Since, TTM earnings of Kalvista Pharmaceuticals Inc (KALV) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Kalvista Pharmaceuticals Inc (KALV) and enter the required number of quantities and click on buy to purchase the shares of Kalvista Pharmaceuticals Inc (KALV).
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts. Address: 55 Cambridge Parkway, Cambridge, MA, United States, 02142
The CEO & director of Mr. Benjamin L. Palleiko. is Kalvista Pharmaceuticals Inc (KALV), and CFO & Sr. VP is Mr. Benjamin L. Palleiko.
There is no promoter pledging in Kalvista Pharmaceuticals Inc (KALV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
414
|
|
|
1
|
|
|
0
|
|
|
9,111
|
|
|
414
|
|
|
1
|
|
|
0
|
|
|
9,111
|
| Kalvista Pharmaceuticals Inc (KALV) | Ratios |
|---|---|
|
Return on equity(%)
|
-110.64
|
|
Operating margin(%)
|
-14601.66
|
|
Net Margin(%)
|
-14582.92
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Kalvista Pharmaceuticals Inc (KALV) was $0 Mln.
$-0.23
(
